Tuberculosis and human immunodeficiency virus co-infected patients’ mortality rate and its predictors in Dire Dawa, Eastern Ethiopia, 2018


  • Samuel Derbie Habtegiorgis Department of Public Health, Debre Markos University, Debre Markos, Amhara, Ethiopia
  • Tariku Dingeta Amante Department of Public Health, Haramaya University, Harar, Ethiopia
  • Pammla Petrucka College of Nursing School of Saskatchewan, Saskatoon, Canada and School of life and bioengineering, Nensal Mandella Institiute of Technology, Tanzania



Dire Dawa, Ethiopia, Retrospective cohort, Mortality rate, TB/ HIV co-infection


Background: Tuberculosis and human immunodeficiency virus (TB/HIV) co-infection is an important global public health problem and result multidirectional tricky. The mortality rate of co-infected patient’s comes from many aspects or factors. Identification of these factors is important for planning and for the intervention of care and treatment. The aim of this study   was to examine the co-infected patients’ mortality rate and its predictors.

Methods: A five-year retrospective cohort study was employed among 471 randomly selected TB/HIV co-infected patients enrolled from January, 2012 to December, 2016. Relevant variables of data were collected from patients ‘medical cards. The collected data were entered into Epi-data and exported to SPSS version 24 for analysis. Univariate analyses were used to describe the baseline characteristics of the patients. Kaplan Meir curve were used for the comparison of time to recovery among the different groups of patients and Cox model was used to identify independent predictors.

Results: A total of 79 (16.8%) deaths occurred during the median follow-up period of 685 days. being infected with pulmonary tuberculosis (PTB) [AHR=1.99 (95% CI:1.16-3.41)], WHO clinical stage III [AHR=2.88 (95% CI:1.56-5.30)], IV [AHR=4.20 (95% CI:2.21-8.01)], ambulatory functional status [AHR=4.15 (95% CI:1.57-10.98)], bedridden functional status [AHR=6.34 (95% CI:2.43-16.59)] and delayed Co-trimoxazole preventive therapy [AHR=2.45 (95% CI:1.54-3.91)] were important predictors associated with high mortality rate of TB/HIV co-infected patients.  

Conclusions: about one to six TB/HIV co-infected persons died in their course of treatment follow-up. Important contributing factors were PTB infection, WHO clinical staging III and IV, ambulatory and bed ridden functional status and delayed co-trimoxazole preventive therapy.


Metrics Loading ...


WHO. Guide to Monitoring and Evaluation for Collaborative TB/HIV Activities--2015. 2015. Available at: item/9789241508278. Accessed on 3 January 2023.

WHO. WHO policy on collaborative TB/HIV activities: guidelines for national programmes and other stakeholders. 2012. Available at: Accessed on 3 January 2023.

Mekonnen D, Derbie A, and E. Desalegn, TB/HIV co-infections and associated factors among patients on directly observed treatment short course in Northeastern Ethiopia: a 4 years retrospective study. BMC research notes, 2015;8(1):666.

Gebrezgabiher G. Treatment outcome of tuberculosis patients under directly observed treatment short course and factors affecting outcome in southern Ethiopia: a five-year retrospective study. PloS one. 2016;11(2):e0150560.

WHO. Definitions and reporting framework for tuberculosis-2013 revision. 2013. Available at: Accessed on 3 January 2023.

Shaweno D, Worku A. Tuberculosis treatment survival of HIV positive TB patients on directly observed treatment short-course in Southern Ethiopia: a retrospective cohort study. BMC Res Notes. 2012;5(1):682.

Federal H. AIDS prevention and control office. Country progress report on HIV/AIDS response. Addis Ababa: FHAPCO. 2014.

Agbor AA. Factors associated with death during tuberculosis treatment of patients co-infected with HIV at the Yaoundé Central Hospital, Cameroon: an 8-year hospital-based retrospective cohort study (2006–2013). PloS one. 2014;9(12):e115211.

Ferreira MD. Predictors of mortality among intensive care unit patients coinfected with tuberculosis and HIV. J Brasileiro de Pneumologia. 2018;44(2):118-24.

Cain KP. Causes of death in HIV-infected persons who have tuberculosis, Thailand. Emerging infectious dis. 2009;15(2):258.

Català L, Orcau A, De Olalla PG, Millet JP, Rodríguez-Mondragón A, Caylà JA et al. Survival of a large cohort of HIV-infected tuberculosis patients in the era of highly active antiretroviral treatment. Int J Tuberculosis Lung Dis. 2011;15(2):263-9.

Vijay S, Kumar P, Chauhan LS, Rao SVL, Vaidyanathan P. Treatment outcome and mortality at one and half year follow-up of HIV infected TB patients under TB control programme in a district of South India. PLoS One. 2011;6(7):e21008.

Ismail I, Bulgiba A. Predictors of death during tuberculosis treatment in TB/HIV co-infected patients in Malaysia. PLoS One. 2013;8(8):e73250.

Teklu AM, Nega A, Mamuye AT, Sitotaw Y, Kassa D, Mesfin G et al. Factors associated with mortality of TB/HIV co-infected patients in Ethiopia. Ethiop J Heal Sci. 2017;27(1):29-38.

Gesesew H. Predictors of mortality in a cohort of tuberculosis/HIV co-infected patients in Southwest Ethiopia. Infect Dis Poverty. 2016;5(1):109.

Abrha H. Survival experience and its predictors among TB/HIV Co-infected patients in Southwest Ethiopia. Epidemiol (Sunnyvale). 2015;5:191.

Refera H, Wencheko E. Survival of HIV-TB co-infected adult patients under ART in Ambo Referral Hospital, Ethiopia. Ethiop J Heal Develop. 2013;27(2):88-93.

Abebe T, Angamo MT. Treatment outcomes and associated factors among tuberculosis patients in Southwest Ethiopia. Greatment Outcom. 2015;57(4):397-407.

Dos Santos RP, Deutschendorf C, Scheid K, Goldani LZ. In-hospital mortality of disseminated tuberculosis in patients infected with the human immunodeficiency virus. Clin Develop Immunol. 2011;2011.

Sileshi B. Predictors of mortality among TB-HIV Co-infected patients being treated for tuberculosis in Northwest Ethiopia: a retrospective cohort study. BMC infectious dis. 2013;13(1):297.






Original Research Articles